GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
764
c/glp1science·posted 11 months ago by u/yannick_barros

appetite is the most under-discussed thing on this board

Needs Source Receipts ×6

appetite is the most under-discussed thing on this board. Change my mind, genuinely — I have no stake in being right about this.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

That is everything I have. The rest is opinion and I have tried to keep it out.

978 up / 214 down82% upvoted44 commentsid xddphw10 Aug 2025

44 comments

27 in this archive, depth 6

best — the order this archive was captured in

u/niels_roos65 points·11 months ago

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

replysharereportpermalink
u/bastian_eriksen-16 points·11 months ago

Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.

replysharereportpermalink
u/camila_mensa54 points·11 months ago

mechanism explains a direction, not a magnitude

replysharereportpermalink
u/yannick_barrosOP29 points·11 months ago

mechanism explains a direction, not a magnitude

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

replysharereportpermalink
u/yannick_barrosOP17 points·11 months ago

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

replysharereportpermalink
u/nadia_fonseca4 points·11 months ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/mod_ambulatoryadmin31 points·11 months ago

Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.

replysharereportpermalink
[removed]47 points·11 months ago

[removed by moderator]

replysharereportpermalink
u/isabela_nilsen25 points·11 months ago

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

replysharereportpermalink
u/aleksi_eriksen30 points·11 months ago

That study was in a rodent model. Worth stating, since the thread has been reading it as human data.

replysharereportpermalink
u/osman_eriksen24 points·11 months ago

read the discussion section, that is where the honesty lives

replysharereportpermalink
u/devils_advocate_d63 points·11 months ago

What was the exposure in that experiment relative to therapeutic?

replysharereportpermalink
u/gastric_emptying_gMOD46 points·11 months ago

Retitled to distinguish preclinical from clinical, which the original ran together.

replysharereportpermalink
u/ingrid_correia66 points·11 months ago

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

replysharereportpermalink
u/priya_guerrero38 points·11 months ago·edited

What was the exposure in that experiment relative to therapeutic?

Agreed — and it is why the central and peripheral stories are complementary rather than rival.

replysharereportpermalink
load more comments (3) →
u/signe_boateng38 points·11 months ago

Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.

replysharereportpermalink
u/ismael_eriksen32 points·11 months ago

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

replysharereportpermalink
u/yannick_barrosOP30 points·11 months ago

albumin binding is most of the half-life story

replysharereportpermalink
u/gastric_emptying_g20 points·11 months ago

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

replysharereportpermalink
u/kian_balogun28 points·11 months ago

half-life is why these are weekly and not daily

replysharereportpermalink
u/nhs_waitlist_nUK41 points·11 months ago

glucagon agonism sounds paradoxical until you read the energy expenditure work

replysharereportpermalink
u/viktor_girard30 points·11 months ago

Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.

replysharereportpermalink
u/bastian_ekstrom44 points·11 months ago

dose response is not linear and nobody should assume it is

replysharereportpermalink
u/nadia_fonseca11 points·11 months ago

receptor distribution is why the side effects are where they are

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.